Leading hematology journal publishes pivotal ELOCTATE™ data that demonstrated efficacy and safety of investigational long-lasting therapy for hemophilia A
Phase 3 study showed potential for once- or twice-weekly prophylactic…
13 November 2013 | By Biogen Idec
Phase 3 study showed potential for once- or twice-weekly prophylactic dosing regimens...